Major players in the blood transfusion diagnostics market are BAG Health Care GmbH, Grifols, Bio-Rad Laboratories Inc. , Abbott Laboratories, Immucor Inc, Ortho Clinical Diagnostics, DiaSorin S. p. A, Siemens Healthcare Private Limited, Thermo Fisher Scientific Inc.
New York, May 27, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Blood Transfusion Diagnostics Global Market Report 2022" - https://www.reportlinker.com/p06280841/?utm_source=GNW
, and Beckman Coulter Inc.
The global blood transfusion diagnostics market is expected to grow from $3.34 billion in 2021 to $3.65 billion in 2022 at a compound annual growth rate (CAGR) of 9.2%. The market is expected to grow to $5.35 billion in 2026 at a compound annual growth rate (CAGR) of 10%.
The blood transfusion diagnostics market consists of sales of blood transfusion diagnostics devices and related services.The related services here include only installation and maintenance services offered by equipment manufacturers.
Blood transfusion diagnostics are the devices used to conduct tests before transfusion of blood from donor-recipient such as blood grouping disease screening.
The main types of blood transfusion diagnostics are instruments and kits, reagents, and others.The blood transfusion diagnostic kits are used to collect and transfuse blood.
The technologies involved in blood transfusion diagnostics are western blot, ELISA, nucleic acid amplification, fluorescence assay, and rapid test that are used for various applications such as blood grouping and disease screening. The end-users involved are hospitals, diagnostic laboratories, blood banks, and plasma fractionation companies.
Patients undergoing surgical procedures need a blood transfusion to replace the lost blood during the procedure.Blood transfusion diagnostics are used during the procedures to screen the blood before transferring it to the patient, and will otherwise increase the incidence of infectious disease.
According to an article published in the US National Library of Medicine, National Institutes of Health, approximately 310 million surgeries are being performed each year. This increase in the number of procedures will thereby drive the need for blood transfusion diagnostics.
Developing and underdeveloped countries lack adequate blood banks, proper medical equipment for blood transfusion, adequate conditions for the storage of blood, and low supply for the high demand of blood.Hospitals are not equipped with proper amenities that help provide hygienic and safe transfusions.
For example, according to research conducted by India Spend, around 1.18 million units of blood were wasted during storage in the form of discoloration, bacterial contamination, and expiry due to outdating. The poor infrastructure hampers the growth of the blood transfusion diagnostic market.
The growing demand for advanced diagnostic measures and growing prevalence of infectious diseases associated with pathogens such as bacteria & viruses increase the preference for nucleic acid amplification testing (NAAT/NAT) to increase blood safety, improve efficiency and reduce the turnaround time of the results.NAT is a technique that helps detect a particular nucleic acid, virus, or bacteria that acts as a pathogen in blood, tissue, or urine.
NAT is highly sensitive and specific for viral nucleic acids and amplifies the region of targeted viral DNA and detects them earlier than the other traditional methods and narrows the period of infectious diseases. For example, XCRP Diagnostic Inc. and Luminex Corporations entered into a licensing agreement of XCR Diagnostic’s Xtreme Chain Reaction Nucleic Acid Amplification Technology. In this deal, Luminex got the exclusive rights to use the XCR Diagnostic’s NAAT technology for their future molecular diagnostic portfolio.
The blood transfusion diagnostics market is highly regulated by governing bodies such as USFDA (the USA Food and Drug Administration), and the Medicines and Healthcare products Agency (MHRA).For instance, the manufacturers and service providers in the USA must comply with the Center for Biologics Evaluation and Research (CBER) Regulations that have been published in the first chapter title 21 of the Code of Federal Regulations (CFR).
Part 600 of CFR 21 primarily focuses on the established standards like retention samples conditions, temperature to be maintained during shipment, sterilization of equipment, and role and duties of the inspector to inspect the laboratories. The regulation also allows the manufacturer to report any kind of deviation of their product from their intended purpose.
The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the blood transfusion diagnostics market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.
Read the full report: https://www.reportlinker.com/p06280841/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
CONTACT: Clare: email@example.com US: (339)-368-6001 Intl: +1 339-368-6001